Axol (Biotechnology) Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 41

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.2M

  • Investors
  • 11

Axol (Biotechnology) General Information

Description

Operator of a biotechnology company intended for medical research, disease modeling, and drug development based in the United Kingdom. The company generates stem cells from blood and tissue cells, extracted from healthy and diseased patients with the aim to develop the best human cell biology research tools to advance medical research and drug discovery for many of the world's biggest and best-known pharma companies and research institutions, enabling researchers to develop treatments based on stem cell research.

Contact Information

Website
www.axolbio.com
Formerly Known As
Tayvin 478
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Corporate Office
  • Roslin Innovation Centre, Charnock Bradley Building
  • Easter Bush Campus, Easter Bush
  • Roslin EH25 9RG
  • Scotland, United Kingdom
+44 0131 000 0000

Axol (Biotechnology) Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axol (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 07-Apr-2022 $4.2M 0000 Completed Generating Revenue
6. Later Stage VC 17-Mar-2021 00.00 000.00 Completed Generating Revenue
5. Early Stage VC 16-Aug-2017 00.000 00.000 00000 Completed Generating Revenue
4. Equity Crowdfunding 24-Mar-2016 00.000 00.000 000.00 Completed Generating Revenue
3. Seed Round 04-Jun-2015 00000 00.000 00.00 Completed Generating Revenue
2. Angel (individual) 21-Aug-2014 $1.35M $1.53M 00.000 Completed Generating Revenue
1. Angel (individual) 01-Jan-2013 $185K $185K 00000 Completed Startup
To view Axol (Biotechnology)’s complete valuation and funding history, request access »

Axol (Biotechnology) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary Shares 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary Shares 000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary Shares 65,645 $0.130441 $2.38 $2.38 1x $2.38 0.54%
Ordinary Shares 87,500 $0.130441 $0.97 $0.97 1x $0.97 0.72%
To view Axol (Biotechnology)’s complete cap table history, request access »

Axol (Biotechnology) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended for medical research, disease modeling, and drug development based in the U
Biotechnology
Roslin, United Kingdom
41 As of 2024
0000
0000000000 0 0000

000000

llum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Vancouver, Canada
0000 As of 0000
000.00
00000000. 00 000.00

00000

on ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolo
0000000000000
Centennial, CO
000.00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Axol (Biotechnology) Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
StemCell Technologies Private Debt Financed Vancouver, Canada 0000 000.00 00000000. 00 000.00
Novus Biologicals Formerly PE-Backed Centennial, CO 000000&0
MORAGA BIOTECHNOLOGY CORPORATION Corporation Los Angeles, CA 0
Miltenyi Biotec Private Debt Financed Bergisch Gladbach, Germany 0000 000000000
BioLegend Corporate Backed or Acquired San Diego, CA 000 000000&0
You’re viewing 5 of 37 competitors. Get the full list »

Axol (Biotechnology) Patents

Axol (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201420853-D0 Methods for differentiation of primate pluripotent stem cells Inactive 24-Nov-2014
GB-201317657-D0 Methods for differentiation of primate pluripotent stem cells Inactive 07-Oct-2013

Axol (Biotechnology) Executive Team (9)

Name Title Board Seat Contact Info
Liam Taylor Chief Executive Officer & Board Member
Ashley Barnes Chief Scientific Officer
Oliver Richardson Finance Director & Board Member
Jonathan Milner Ph.D Co-Founder & Chairman
You’re viewing 4 of 9 executive team members. Get the full list »

Axol (Biotechnology) Board Members (9)

Name Representing Role Since
Derek Tresize Axol (Biotechnology) Board Member 000 0000
Jonathan Milner Ph.D Axol (Biotechnology) Co-Founder & Chairman 000 0000
Liam Taylor Axol (Biotechnology) Chief Executive Officer & Board Member 000 0000
Oliver Richardson Axol (Biotechnology) Finance Director & Board Member 000 0000
Thomas Stratford Ph.D Self Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Axol (Biotechnology) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axol (Biotechnology) Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cleevely & Partners Venture Capital Minority 000 0000 000000 0
Jonathan Milner Angel (individual) Minority 000 0000 000000 0
Meltwind Advisory Venture Capital Minority 000 0000 000000 0
Calculus Capital PE/Buyout Minority 000 0000 000000 0
Par Equity Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Axol (Biotechnology) Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Censo Biotechnologies 17-Mar-2021 0000000000 00.00 Biotechnology 0000 0000
To view Axol (Biotechnology)’s complete investments history, request access »

Axol (Biotechnology) FAQs

  • When was Axol (Biotechnology) founded?

    Axol (Biotechnology) was founded in 2012.

  • Who is the founder of Axol (Biotechnology)?

    Yichen Shi Ph.D and Jonathan Milner Ph.D are the founders of Axol (Biotechnology).

  • Who is the CEO of Axol (Biotechnology)?

    Liam Taylor is the CEO of Axol (Biotechnology).

  • Where is Axol (Biotechnology) headquartered?

    Axol (Biotechnology) is headquartered in Roslin, United Kingdom.

  • What is the size of Axol (Biotechnology)?

    Axol (Biotechnology) has 41 total employees.

  • What industry is Axol (Biotechnology) in?

    Axol (Biotechnology)’s primary industry is Biotechnology.

  • Is Axol (Biotechnology) a private or public company?

    Axol (Biotechnology) is a Private company.

  • What is Axol (Biotechnology)’s current revenue?

    The current revenue for Axol (Biotechnology) is 000000.

  • How much funding has Axol (Biotechnology) raised over time?

    Axol (Biotechnology) has raised $17M.

  • Who are Axol (Biotechnology)’s investors?

    Cleevely & Partners, Jonathan Milner, Meltwind Advisory, Calculus Capital, and Par Equity are 5 of 11 investors who have invested in Axol (Biotechnology).

  • Who are Axol (Biotechnology)’s competitors?

    StemCell Technologies, Novus Biologicals, MORAGA BIOTECHNOLOGY CORPORATION, Miltenyi Biotec, and BioLegend are some of the 37 competitors of Axol (Biotechnology).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »